LYEL Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of --. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling downside risk potential of -20.61%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 933.73%. Given that GT Biopharma, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are larger than GT Biopharma, Inc. quarterly revenues of --. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 135,511.28x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -82.06%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling downside risk potential of -20.61%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 8.17%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 135,511.28x versus 13.85x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -9210.61%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling downside risk potential of -20.61%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 126.2%. Given that Ovid Therapeutics, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 135,511.28x versus 19.25x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of 38.89%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Lyell Immunopharma, Inc. has a consensus price target of $29.67, signalling downside risk potential of -20.61%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 1.35%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 135,511.28x versus 6.03x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.